KMPH KemPharm 8-K2021Sven Guenther, Ph.D., our executive vice president, research and development; and Summary Compensation Table
5 Jan 21
Files
SEC
Content Analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
|
|
KMPH 8-K Filings
- 13 Jan 21 KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital Market
- 5 Jan 21 Sven Guenther, Ph.D., our executive vice president, research and development; and Summary Compensation Table
- 28 Dec 20 Entry into a Material Definitive Agreement
- 28 Dec 20 KemPharm Announces 1-for-16 Reverse Stock Split
- 21 Dec 20 Entry into a Material Definitive Agreement
Filing View
Search this filing
Table of Contents
Get all this for free
- Email alerts for new filings that match keywords or companies
- Plot, compare & download financial data
- 10-K & 10-Q redlined comparisons
- Advanced filing search & analysis
- Sentiment analysis for financial filings
- Favorites, search history, and more…